14,042
Total Claims
$1.4M
Drug Cost
965
Beneficiaries
$1,439
Cost/Patient
Peer Comparison vs. 110,156 Internal Medicine providers
+2%
Cost per patient vs peers
$1,439 vs $1,411 avg
+18%
Brand preference vs peers
12.6% vs 10.6% avg
Brand vs Generic
87% generic
Brand: 1,746 claims · $1.2M
Generic: 12,144 claims · $222K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 64 | $137K |
| Sitagliptin Phosphate | 65 | $83K |
| Linagliptin | 59 | $75K |
| Apixaban | 56 | $71K |
| Mirabegron | 54 | $68K |
| Dapagliflozin Propanediol | 41 | $67K |
| Denosumab | 35 | $59K |
| Semaglutide | 38 | $52K |
| Insulin Aspart Prot/Insuln Asp | 20 | $50K |
| Sitagliptin Phos/Metformin Hcl | 28 | $36K |
| Insulin Glargine,hum.Rec.Anlog | 35 | $35K |
| Rivaroxaban | 33 | $35K |
| Insulin Detemir | 22 | $22K |
| Insulin Detemir | 11 | $21K |
| Empagliflozin | 11 | $20K |
Prescribing Profile
Patient Profile
76
Avg Age
80%
Female
1.11
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data